Cited 0 times in
CYP2C19 유전자 다형성에 따른 VerifyNow P2Y12 검사와 뇌졸 중 재발 관련성
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남효석 | - |
dc.contributor.author | 이경열 | - |
dc.date.accessioned | 2019-05-29T05:18:24Z | - |
dc.date.available | 2019-05-29T05:18:24Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 2508-626X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/169520 | - |
dc.description.abstract | Background and Purpose: To perform a subgroup analysis of MAESTRO study to explore the relationship between VerifyNow P2Y12 assay and stroke recurrence with regard to CYP2C19 polymorphisms. Methods: Patients who underwent clopidogrel treatment and VerifyNow assay in the MAESTRO study were analyzed. For the study, the efficacy and safety of clopidogrel t treatment for the secondary prevention of ischemic stroke and major vascular event were compared based on CYP2C19 polymorphisms and VerifyNow P2Y12 assay. Results:Two hundred fifty-six patients were entered for this subgroup analysis. The median duration of follow-up was 3.0 years. Thirteen (5.1%) patients had a recurrent stroke: 10 (77%) experienced an ischemic stroke and 3 (23%) experienced an intracerebral hemorrhage. In patients with percent inhibition (% INH) ≥40, the risk of recurrent stroke in the good genotype group was 2.0% and was not significantly different from that in the poor genotype group (4.8%) (P=0.536). In patients with % INH <40, there was no reduction in risk for recurrent stroke in the good genotype group (2.2% vs 6.7%, P=0.225). Though there were no significant differences, a trend toward having more number of recurrent ischemic stroke was observed in % INH <40 and poor genotype group. The risk of recurrent ischemic stroke in the % INH ≥40 and good genotype group was 0% and was 6.7% in the % INH <40 and poor genotype group (P=0.06). Conclusions: Ex vivo platelet function test relating to genetic polymorphisms did not predict stroke recurrence during clopidogrel treatment. | - |
dc.description.statementOfResponsibility | prohibition | - |
dc.language | Korean | - |
dc.publisher | 부산·울산·경남 뇌졸중학회 | - |
dc.relation.isPartOf | Journal of Vascular Neurology | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | CYP2C19 유전자 다형성에 따른 VerifyNow P2Y12 검사와 뇌졸 중 재발 관련성 | - |
dc.title.alternative | Relationship between VerifyNow P2Y12 assay for CYP2C19 polymorphisms and stroke recurrence | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학교실) | - |
dc.contributor.googleauthor | 한상원 | - |
dc.contributor.googleauthor | 김용재 | - |
dc.contributor.googleauthor | 서우근 | - |
dc.contributor.googleauthor | 유성욱 | - |
dc.contributor.googleauthor | 남효석 | - |
dc.contributor.googleauthor | 윤성상 | - |
dc.contributor.googleauthor | 김서현 | - |
dc.contributor.googleauthor | 이종윤 | - |
dc.contributor.googleauthor | 이준홍 | - |
dc.contributor.googleauthor | 황양하 | - |
dc.contributor.googleauthor | 이준 | - |
dc.contributor.googleauthor | 이경아 | - |
dc.contributor.googleauthor | 이경열 | - |
dc.contributor.localId | A01273 | - |
dc.contributor.localId | A02648 | - |
dc.relation.journalcode | J03607 | - |
dc.subject.keyword | clopidogrel | - |
dc.subject.keyword | polymorphisms | - |
dc.subject.keyword | stroke | - |
dc.subject.keyword | VerifyNow | - |
dc.contributor.alternativeName | Nam, Hyo Suk | - |
dc.contributor.affiliatedAuthor | 남효석 | - |
dc.contributor.affiliatedAuthor | 이경열 | - |
dc.citation.volume | 3 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 16 | - |
dc.citation.endPage | 22 | - |
dc.identifier.bibliographicCitation | Journal of Vascular Neurology, Vol.3(1) : 16-22, 2018 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.